Shimla, Nov 21,
The Himachal Pradesh High Court has ordered a probe into allegations of substandard drug manufacturing in the Baddi industrial area.
The directive came in response to a petition filed by Themis Medicare Limited, which raised concerns about the production of subpar Feracrylum API and 1% Feracrylum gel. The petition, highlighted the public health risks posed by non-compliant medicines, particularly “Feracrylum API” and “1% Feracrylum Gel.” The petitioner alleged that the composition of these drugs does not conform to prescribed standards. Despite repeated complaints, no action had been initiated, raising concerns about regulatory oversight in safeguarding public health.
The petitioner argued that these drugs, crucial for controlling bleeding, were being manufactured in violation of prescribed formulas, potentially endangering patient safety. Despite multiple complaints to the State Drugs Controller, no significant action had been taken.
The court led by Justice Sandeep Sharma recognizing the gravity of the issue, directed the State Drugs Controller to conduct a thorough investigation within two weeks. The order mandates that the concerned authority must provide a fair hearing to all parties involved and issue a detailed, reasoned order.
As the matter was disposed the court clarified that the petitioner retains the liberty to pursue further legal remedies if dissatisfaction persists following the regulatory action.
Empower Independent Journalism – Join Us Today!
Dear Reader,
We’re committed to unbiased, in-depth journalism that uncovers truth and gives voice to the unheard. To sustain our mission, we need your help. Your contribution, no matter the size, fuels our research, reporting, and impact.
Stand with us in preserving independent journalism’s integrity and transparency. Support free press, diverse perspectives, and informed democracy.
Click [here] to join and be part of this vital endeavour.
Thank you for valuing independent journalism.
Warmly,
Vishal Sarin, Editor
